人脂多糖模型为全身与肺部炎症提供机制与治疗见解
脓毒症和急性呼吸窘迫综合征(ARDS)死亡率高,早期炎症事件难以在临床中研究。人脂多糖(LPS)模型给予健康志愿者少量LPS触发炎症反应,提供研究早期炎症的窗口。本文综述静脉和肺部LPS挑战的机制见解,讨论影响LPS反应的因素及未来研究设计考虑。
要点
- 人LPS模型可研究脓毒症和ARDS早期炎症机制。
- 静脉和肺部LPS挑战提供可控可重复的炎症研究环境。
- 设计未来人LPS研究需考虑影响反应的因素。
核心结论
- 人LPS模型为研究全身和肺部炎症的早期机制及测试新治疗策略提供可控可重复的平台。
研究设计与样本
- 综述人LPS模型的应用,聚焦静脉和肺部LPS挑战的机制见解。
主要发现
- 人LPS模型给予健康志愿者少量LPS触发炎症反应,可研究早期炎症。
- 通过静脉和肺部LPS挑战获得了炎症的生物学/机制见解。
临床怎么用
- 人LPS模型可用于在定义的时间点开始、可控可重复的环境中测试新治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammation is a key feature in the pathogenesis of sepsis and acute respiratory distress syndrome (ARDS). Sepsis and ARDS continue to be associated with high mortality. A key contributory factor is the rudimentary understanding of the early events in pulmonary and systemic inflammation in humans, which are difficult to study in clinical practice, as they precede the patient's presentation to medical services. Lipopolysaccharide (LPS), a constituent of the outer membrane of Gram-negative bacteria, is a trigger of inflammation and the dysregulated host response in sepsis. Human LPS models deliver a small quantity of LPS to healthy volunteers, triggering an inflammatory response and providing a window to study early inflammation in humans. This allows biological/mechanistic insights to be made and new therapeutic strategies to be tested in a controlled, reproducible environment from a defined point in time. We review the use of human LPS models, focussing on the underlying mechanistic insights that have been gained by studying the response to intravenous and pulmonary LPS challenge. We discuss variables that may influence the response to LPS before considering factors that should be considered when designing future human LPS studies.
引用
- Brooks D, Barr LC, Wiscombe S, et al. Human lipopolysaccharide models provide mechanistic and therapeutic insights into systemic and pulmonary inflammation. Eur Respir J. 2020. PMID: 32299854. doi:10.1183/13993003.01298-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。